Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended 31 March 2015
Key Event: Completion of the three-part transaction with Novartis on 2 March 2015, involving the exchange of GSK's Oncology business for Novartis' Vaccines and Consumer Healthcare businesses. This created a new balanced group structure comprising Pharmaceuticals, Vaccines, and Consumer Healthcare.
Key Financial Metrics (Q1 2015)
| Metric | Value | Change (CER) |
|---|---|---|
| Turnover | £5.62 billion | +1% |
| Core Operating Profit | £1.31 billion | -14% |
| Core Operating Margin | 23.2% | -4.1 percentage points |
| Core Earnings Per Share (EPS) | 17.3p | -16% |
| Total EPS (including non-core items) | 167.8p | >100% |
| Net Debt | £8.1 billion | Decreased from £14.4 billion (Dec 2014) |
| Free Cash Flow | £(69) million | Negative (vs £467m in Q1 2014) |
| Dividend Declared | 19 pence per share | Flat vs Q1 2014 |
Note: CER = Constant Exchange Rate. Total EPS includes a pre-tax transaction gain of £9.3 billion from the Oncology disposal.
Material Changes vs. Prior Period
- Revenue Mix: Total Pharmaceuticals sales declined 7% (CER) due to a 12% drop in Global Pharmaceuticals (driven by Advair pricing pressure and Oncology divestment), partially offset by a 42% surge in ViiV Healthcare sales. Vaccines (+10%) and Consumer Healthcare (+24%) grew significantly, aided by the Novartis acquisition.
- Profitability: Core operating profit fell 14% due to margin compression in Pharmaceuticals and the dilutive impact of the transaction. However, Total Operating Profit surged to £9.2 billion due to the £9.3 billion gain on the disposal of the Oncology business.
- Balance Sheet: Net debt reduced by approximately £6.3 billion, reflecting £10.1 billion in net cash proceeds from the Oncology sale and £3.3 billion paid for the Novartis businesses.
- Segment Performance:
- Pharmaceuticals: Respiratory sales down 9% (Advair/Seretide down 14%).
- ViiV Healthcare: Sales up 42% driven by Tivicay and Triumeq.
- Consumer Healthcare: Sales up 24% (8% pro-forma), driven by Flonase OTC launch and Oral Health strength.
Guidance, Outlook, and Management Commentary
2015 Guidance
Core EPS is expected to decline in the high teens (CER) for the full year 2015. This is attributed to pricing pressure on Advair, the dilutive effect of the Novartis transaction, and the inherited cost base of the acquired businesses.
2016-2020 Outlook
- Revenue Growth: Expected CAGR of low-to-mid single digits (CER).
- Vaccines: Mid-to-high single digits.
- Consumer Healthcare: Mid single digits.
- Pharmaceuticals: Low single digits (factoring in potential US generic Advair).
- Earnings Growth: Core EPS expected to grow at a CAGR of mid-to-high single digits (CER). A significant recovery is anticipated in 2016 with double-digit growth.
- Restructuring: Accelerated synergy program targeting £3 billion in total annual benefits by end of 2017. Over 50% of transaction synergies (£1 billion total) now expected in 2016.
Capital Allocation
- Dividends: Annual ordinary dividend of 80p per share for 2015, 2016, and 2017.
- Special Dividend: Reduced return of transaction proceeds to £1 billion, to be paid as a special dividend in Q4 2015.
- Strategy: Retention of full holding in ViiV Healthcare (no IPO planned) due to strong outlook. Cash prioritized for dividends, synergy investments, and flexibility for potential put options (ViiV/Consumer Healthcare) and generic Advair risks.
Risks and Contingencies
- Generic Competition: Continued decline in Advair/Seretide sales; potential introduction of generic Advair in the US factored into long-term guidance.
- Put Options: Potential obligation to buy out partners in ViiV Healthcare (Pfizer/Shionogi) and Consumer Healthcare (Novartis) at market valuation.
- Legal: Ongoing litigation and tax disputes; aggregate provision for legal disputes is £0.5 billion.
Investor Verification Checklist
- Advair Exposure: Verify the timeline and impact of potential generic entry for Advair in the US market on Pharmaceutical margins.
- Restructuring Execution: Monitor the delivery of the accelerated £3 billion synergy program and the associated cash charges (£3.65 billion total).
- Put Option Liability: Review the valuation and probability of the £6.2 billion liability associated with the Novartis put option in the Consumer Healthcare joint venture.
- ViiV Performance: Track sales growth of Tivicay and Triumeq to validate the decision to retain the full stake rather than pursue an IPO.
- Free Cash Flow: Assess the recovery of free cash flow conversion, which was negative in Q1 2015 due to restructuring outflows and transaction costs.